Laprophan Completes the Acquisition of Rivopharm, Accelerating Its International Expansion Strategy
Laprophan Group, the pioneer and one of Morocco's leading pharmaceutical groups, today announced the successful completion of the acquisition of a controlling stake in Rivopharm, a Switzerland-based pharmaceutical company specialized in specialty medicines, dossier development, complex formulations and value-added pharmaceutical solutions, and operating its own industrial manufacturing site. The financial terms of the transaction were not disclosed. Rivopharm generates annual revenue of approximately US$100 million.
The acquisition represents a transformational milestone in Laprophan's development and marks the Group's first acquisition in Europe. The transaction significantly strengthens Laprophan's European footprint and accelerates its ambition to build a differentiated international pharmaceutical platform spanning Europe, Africa, the Middle East and selected global markets.
The acquisition was carried out through Europhan, Laprophan's Luxembourg-based European platform, reinforcing the Group's long-term ambition to structure its international expansion from a strategic European hub.
